Novel Cardiac Precursor-Like Cells from Human Menstrual Blood-Derived Mesenchymal Cells
Article first published online: 17 APR 2008
Copyright © 2008 AlphaMed Press
Volume 26, Issue 7, pages 1695–1704, July 2008
How to Cite
Hida, N., Nishiyama, N., Miyoshi, S., Kira, S., Segawa, K., Uyama, T., Mori, T., Miyado, K., Ikegami, Y., Cui, C., Kiyono, T., Kyo, S., Shimizu, T., Okano, T., Sakamoto, M., Ogawa, S. and Umezawa, A. (2008), Novel Cardiac Precursor-Like Cells from Human Menstrual Blood-Derived Mesenchymal Cells. STEM CELLS, 26: 1695–1704. doi: 10.1634/stemcells.2007-0826
- Issue published online: 2 JAN 2009
- Article first published online: 17 APR 2008
- Manuscript Accepted: 6 APR 2008
- Manuscript Received: 2 OCT 2007
- Cardiomyogenesis human mesenchymal stem cell;
- Menstrual blood endometrial gland;
- Cell sheet technology cardiac precursors
Stem cell therapy can help repair damaged heart tissue. Yet many of the suitable cells currently identified for human use are difficult to obtain and involve invasive procedures. In our search for novel stem cells with a higher cardiomyogenic potential than those available from bone marrow, we discovered that potent cardiac precursor-like cells can be harvested from human menstrual blood. This represents a new, noninvasive, and potent source of cardiac stem cell therapeutic material. We demonstrate that menstrual blood-derived mesenchymal cells (MMCs) began beating spontaneously after induction, exhibiting cardiomyocyte-specific action potentials. Cardiac troponin-I-positive cardiomyocytes accounted for 27%–32% of the MMCs in vitro. The MMCs proliferated, on average, 28 generations without affecting cardiomyogenic transdifferentiation ability, and expressed mRNA of GATA-4 before cardiomyogenic induction. Hypothesizing that the majority of cardiomyogenic cells in MMCs originated from detached uterine endometrial glands, we established monoclonal endometrial gland-derived mesenchymal cells (EMCs), 76%–97% of which transdifferentiated into cardiac cells in vitro. Both EMCs and MMCs were positive for CD29, CD105 and negative for CD34, CD45. EMCs engrafted onto a recipient's heart using a novel 3-dimensional EMC cell sheet manipulation transdifferentiated into cardiac tissue layer in vivo. Transplanted MMCs also significantly restored impaired cardiac function, decreasing the myocardial infarction (MI) area in the nude rat model, with tissue of MMC-derived cardiomyocytes observed in the MI area in vivo. Thus, MMCs appear to be a potential novel, easily accessible source of material for cardiac stem cell-based therapy.
Disclosure of potential conflicts of interest is found at the end of this article.